Gabapentin Enacarbil: Clinical Trials

19 trials of Gabapentin Enacarbil, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 1 recruiting, 1 withdrawn. 5 Phase 3, 4 Phase 1, 4 Phase 2, 3 Phase 4, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5
Phase 14Completed 3, Withdrawn 1
Phase 24Completed 4
Phase 43Completed 2, Recruiting 1
Not applicable2Completed 2

Follow Gabapentin Enacarbil: new trials by email Literature Review of Gabapentin Enacarbil trials Research Report on Gabapentin Enacarbil

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Gabapentin Enacarbil, Placebo Oral Tablet - Alzheimer Disease
Phase 4RecruitingUniversity of Texas at Austin1562017-07-012022-05-18
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Placebo, Gabapentin enacarbil - Restless Legs Syndrome (RLS)
Phase 4CompletedAstellas Pharma Inc3752017-03-302024-12-12
The Effect of Horizant (Gabapentin Enacarbil) on Augmentation
Horizant - Restless Legs Syndrome
Not applicableCompletedUniversity of Missouri-Columbia102016-01-012022-02-24
A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
HORIZANT 300 mg - RLS
Phase 1WithdrawnXenoPort, Inc.2016-01-012021-04-12
Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores
Gabapentin enacarbil, Placebo - Pain
Not applicableCompletedThe Cleveland Clinic1072016-01-012024-01-09
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
gabapentin enacarbil, Placebo - Alcohol Use Disorder
Phase 2CompletedNational Institute on Alcohol Abuse and Alcoholism (NIAAA)3462015-06-012018-11-14
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
Gabapentin enacarbil - Restless Legs Syndrome (RLS)
Phase 4CompletedAstellas Pharma Inc192013-11-052024-11-08
Specified Drug Use-Results Survey of Regnite
Regnite - Restless Legs Syndrome
CompletedAstellas Pharma Inc15972012-10-012019-04-29
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
gabapentin enacarbil, diphenhydramine, placebo - Restless Legs Syndrome (RLS)
Phase 1CompletedXenoPort, Inc.362011-06-012013-07-16
ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825
ASP8825 - Healthy Volunteers
Phase 1CompletedAstellas Pharma Inc182009-01-012015-12-16
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
GSK1838262 Extended Release Tablets, Placebo - Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Phase 3CompletedXenoPort, Inc.1362008-10-012013-07-22
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
GEn 1200mg/day, GEn 3600mg/day - Neuralgia, Postherpetic
Phase 2CompletedXenoPort, Inc.962008-03-012013-07-22
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
Placebo, GEn 1200mg/day, GEn 2400mg/day - Neuropathy, Diabetic
Phase 2CompletedXenoPort, Inc.4212008-03-012013-07-22
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day - Neuralgia, Postherpetic
Phase 2CompletedXenoPort, Inc.3762008-02-012013-07-22
ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis
ASP8825 - Patients With Impaired Renal Function and Haemodialysis
Phase 1CompletedAstellas Pharma Inc182008-02-012016-02-04
Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
ASP8825 - Restless Legs Syndrome
Phase 3CompletedAstellas Pharma Inc1822007-12-012016-02-04
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
XP13512 600MG, XP13512 1200MG, PLACEBO - Restless Legs Syndrome
Phase 3CompletedXenoPort, Inc.3252006-08-012013-07-22
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
XP13512 (GEn) - Restless Legs Syndrome
Phase 3CompletedXenoPort, Inc.5812006-06-012013-07-22
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
GEn (XP13512), Placebo - Restless Legs Syndrome
Phase 3CompletedXenoPort, Inc.3272006-04-012013-07-22

Conditions studied

Restless Legs Syndrome (11)  ·  Neuralgia (3)  ·  Neuralgia, Postherpetic (2)  ·  Alcohol Drinking (1)  ·  Alcoholism (1)  ·  Alzheimer Disease (1)  ·  Diabetic Neuropathies (1)  ·  Pain (1)  ·  Parasomnias (1)  ·  Renal Insufficiency (1)

Sponsors

XenoPort, Inc. (9)  ·  Astellas Pharma Inc (6)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1)  ·  The Cleveland Clinic (1)  ·  University of Missouri-Columbia (1)  ·  University of Texas at Austin (1)

Countries

United States (10)  ·  Japan (6)  ·  Canada (1)  ·  Germany (1)

Top investigators

Daniel Sessler, M.D. (1)  ·  Kathy Richards, PhD (1)  ·  Pradeep Sahota, MD (1)  ·  Raye Z. Litten, Ph.D. (1)  ·  Steven Caras, MD (1)

Results publications

PMID 21527006, PMID 21677899, PMID 23186035, PMID 24102928, PMID 26788345, PMID 27067343, PMID 27288210, PMID 32966585

NIH funding

R01AG051588 (1)